GANX
USDGain Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.810
High
$1.810
Low
$1.660
Volume
0.57M
Company Fundamentals
Market Cap
59.7M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.68M
Exchange
NGM
Currency
USD
52-Week Range
Related News
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to
Related Stocks
ABVEW
Above Food Ingredients Inc. Warrants
UHG
United Homes Group Inc
NNVC
NanoViricides Inc.
NKGN
NKGen Biotech Inc.
KTH
Structures Products Cp 8% CorTS Issued by Peco Energy Cap Tr II Preferred Stock
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.